In the first 10 months, China's exports increased by 13% year-on-year, how did the pharmaceutical equipment industry perform?

【Pharmaceutical Network Market Analysis】On November 7, the General Administration of Customs released data showing that in the first 10 months of this year, China's total import and export value was 34.
62 trillion yuan, an increase of 9.
5%
over the same period last year (the same below).
Among them, exports were 19.
71 trillion yuan, an increase of 13%; imports were 14.
91 trillion yuan, an increase of 5.
2%; The trade surplus was 4.
8 trillion yuan, an increase of 46.
7%.

It is reported that since the beginning of this year, the state has introduced a series of policies and measures to protect the main body of the market, and the customs has also introduced a number of rescue measures to help enterprises, which has effectively stimulated the market vitality
of foreign trade enterprises.
So, how are the exports of the pharmaceutical equipment industry this year? In the first 10 months, China's exports increased by 13% year-on-year, how did the pharmaceutical equipment industry perform? (Image source: Pharmaceutical Network) From the perspective of the more representative domestic head enterprises Dongfulong and Chutian Technology, although there are many challenges during the year, the pace of international development of pharmaceutical machinery enterprises has not stopped
.
Dongfulong is an early domestic pharmaceutical equipment overseas enterprise, the company began to export products overseas in 1999, and successively set up overseas subsidiaries to strengthen localized marketing and services, establish joint ventures and carry out technical cooperation with partners in the United States, Europe, Japan and other partners, and continuously enhance the influence of international brands, and the number of overseas customers and coverage areas have gradually expanded
。 In terms of promoting the process of internationalization, Dongfulong has some advantages, the company mentioned technological breakthroughs, brand building, professional services and process accumulation in the 2022 half-year report, and said that the company's products have been recognized by developed countries such as Europe and the United States and serve foreign pharmaceutical companies, and began to participate in the competition in the
international market.
In the first half of 2022, the company's operating income in Asia increased by 146.
64% over the same period of the previous year, the operating income in North America increased by 99.
32% year-on-year, and the operating income in Europe, Africa and South America all decreased
year-on-year.
In terms of products, Dongfulong's injections, solid preparations, biological macromolecules, cells and gene equipment and other products grew steadily in the first half of the year, among which benefiting from the global development trend and capacity construction of biological macromolecular drugs such as antibodies and vaccines, the company's biological stock solution-related equipment has gained more domestic and foreign market opportunities, and the overall solution capability of biological macromolecular equipment has continued to improve
.
Judging from the information in the third quarterly report of 2022, the operating income of Dongfulong from January to September 2022 increased by 32.
43% compared with the same period of the previous year, mainly due to the increase in
the company's domestic and international order delivery in the current period.
It can be seen that from January to September this year, the company's order delivery in terms of internationalization is better
.
Chutian Technology also has an early layout in terms of internationalization, and the company has sold products to Indonesia since 2002 and began to expand overseas markets
.
In 2017, the company started the acquisition of products and services covering more than 180 countries and regions around the world, including the German Romaco Group in developed countries in Europe and the United States, and merged it into the listed company as a whole in 2020, thus accelerating the pace of international layout, and the company's overseas revenue accounted for nearly 35%
in 2021.
In May this year, Chutian Technology announced the establishment of sales and service centers (SSCs) in 13 countries to further expand the international market
.
At present, the company has entered a new era of internationalization, and the influence of enterprises in the international market has been continuously improved
.
From the perspective of the international business composition of Chutian Technology, it mainly includes two parts, one is all the business of German Romaco, and the other is the export business
of domestic main companies.
In an institutional research activity this year, Chutian Technology mentioned that in the first half of the year, the export business of domestic companies increased relatively large year-on-year, and Romaco was affected by many factors, the delivery cycle slowed down, and the revenue did not meet expectations
.
Romaco Group's operating income in the first half of this year was 531 million yuan, down 23.
34% from the same period of the previous year, and the net profit was -47.
5303 million yuan, down 405.
08%
from the same period of the previous year.
In the company's recent three quarterly reports, it was also mentioned that Romaco Group was affected by many parties, and the project delivery was delayed, resulting in a decline
in project costs and project expenses.
However, the company's development expenditure increased by 14.
7406 million yuan from the beginning of the period, an increase of 40.
83%, mainly due to the increase in
Romaco Group's investment in new product research and development.
At present, the domestic sales scale of Chutian Technology is greater than that of the world, and the company plans to have international sales greater than domestic
in the future.
On July 26, Chutian Technology said in a survey that this year's headquarters plans to double the growth of new orders for export business compared with 2021, and it is planned that by 2025, export business revenue will account for about
50% of total revenue.
Around 2030, the proportion of export business will be even higher
.
At present, the quality of products is constantly improving, which is close to the European level, and it is hoped that ROMACO will maintain a certain growth every year and achieve sales of 300 million euros by 2025
.
In order to lay out the international market, Chutian Technology also revealed in the institutional survey in August this year that the company's international business sales and service personnel have increased to more than 300 people, and established sales and service centers in key countries and regions to vigorously explore overseas markets and continuously improve the company's international sales
.
Conclusion On the whole, the pharmaceutical machinery enterprises represented by the head are full of confidence and determination
in terms of international layout.
However, it should also be noted that compared with foreign head enterprises, domestic pharmaceutical machinery enterprises have certain deficiencies in capital scale, capacity construction, technology, core technology, etc.
, resulting in domestic pharmaceutical machinery enterprises and overseas head pharmaceutical machine manufacturers in a weak position in the process of competing for high-end customers, domestic pharmaceutical machine products have a low international market share, and the internationalization process is slow
.
In the future, domestic pharmaceutical machinery enterprises need to attach importance to R&D and innovation, continue to increase R&D investment, make continuous breakthroughs in automation, informatization, intelligence, continuous production, etc.
, narrow the gap with overseas leading pharmaceutical machinery enterprises, and enhance international competitiveness
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.